Madrigal Pharmaceuticals (MDGL) EBIT Margin (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) reported EBIT Margin of 29.78% for Q1 2026, up 2800.0% year-over-year from 1.03% in Q1 2025, and down 60.42% quarter-over-quarter from 18.56% in Q4 2025.
Madrigal Pharmaceuticals (MDGL) EBIT Margin (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has 6 years of EBIT Margin data on file, last reported at 29.78% in Q1 2026.
- EBIT Margin for Q1 2026 came in at 29.78%, up 2800.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 27.68% (up 10627.0% YoY), and the FY2025 annual result was 31.31%, up 24508.0% from the prior year.
- EBIT Margin slipped to 29.78% in Q1 2026 per MDGL's latest filing, from 18.56% in the prior quarter.
- Over five years, EBIT Margin peaked at 18.56% in Q4 2025 and troughed at 1110.38% in Q2 2024.
- A 3-year average of 191.28% and a median of 48.73% in 2025 frame the typical range for EBIT Margin.
- The sharpest annual moves came in 2025 and 2026: EBIT Margin surged 108820 bps in 2025, then soared 2800 bps in 2026.
- A 3-year view of EBIT Margin shows it stood at 64.84% in 2024, then jumped by 71 bps to 18.56% in 2025, then tumbled by 60 bps to 29.78% in 2026.
- Business Quant data shows MDGL's EBIT Margin at 29.78% in Q1 2026, 18.56% in Q4 2025, and 39.68% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Madrigal Pharmaceuticals | 14.67 Bn | 14.44 Bn | - | -29.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.78% |
| Dec 31, 2025 | -18.56% |
| Sep 30, 2025 | -39.68% |
| Jun 30, 2025 | -22.18% |
| Mar 31, 2025 | -57.79% |
| Dec 31, 2024 | -64.84% |
| Sep 30, 2024 | -187.06% |
| Jun 30, 2024 | -1,110.38% |
| Mar 31, 2012 | -9,908.16% |
| Dec 31, 2011 | -299.12% |
| Sep 30, 2011 | -2,345.11% |
| Jun 30, 2011 | -5,691.47% |
| Mar 31, 2011 | -959.41% |
| Dec 31, 2010 | -207.21% |
| Sep 30, 2010 | -302.42% |
| Jun 30, 2010 | -269.17% |